HOME >> BIOLOGY >> NEWS
Other highlights in the August 18 JNCI

Chromosomal Regions Containing Possible Prostate Cancer Susceptibility Genes Identified

A new study has identified five chromosomal regions that are likely to harbor prostate cancer susceptibility genes.

Prostate cancer is the second leading cause of cancer death among men in the United States. Family history is one of the most well-established risk factors for the disease, but no genes that confer prostate cancer susceptibility have been found to date.

In an analysis of 426 families with histories of prostate cancer, Jeffrey M. Trent, Ph.D., of the Translational Genomics Research Institute in Phoenix, and Jianfeng Xu, M.D., Dr.PH., of Wake Forest University School of Medicine in Winston-Salem, N.C., and colleagues found evidence of a prostate cancer susceptibility gene on the long arm of chromosome 17. In addition, four other regions that might hold susceptibility genes were identified among specific subsets of families. Further fine mapping studies will be needed to identify any prostate cancer susceptibility genes in these regions, the authors say.

Contacts:

  • Wake Forest University: Karen Richardson (krchrdsn@wfubmc.edu) or Shannon Koontz (shkoontz@wfubmc.edu), 336-716-4587
  • TGen: Galen Perry, Director of Communications, 602-343-8423, gperry@tgen.org

    Gene Mutation Associated With Lower Risk of Prostate Cancer Found

    Men who carry a specific mutation in the MIC-1 gene may have a lower risk of developing prostate cancer than men who do not have the mutation, according to a new study. Henrik Grnberg, Ph.D., of Ume University in Ume, Sweden, and colleagues had hypothesized that variations in the MIC-1 gene, which is thought to play an important role in the inflammatory response to infection, could be associated with the risk of prostate cancer.

    Contact: Henrik Grnbe
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oupjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    17-Aug-2004


    Page: 1 2 3

    Related biology news :

    1. Other highlights in the September 1 JNCI
    2. Other highlights in the August 4 JNCI
    3. Other highlights in the July 7 JNCI
    4. Other highlights in the June 16 JNCI
    5. Other Highlights in the June 2 JNCI
    6. Other highlights in the May 19 JNCI
    7. Other highlights in the May 5 JNCI
    8. Other highlights of the March 17 issue of JNCI
    9. Other highlights in the March 3 issue of JNCI
    10. Other highlights in the February 18 issue of JNCI
    11. Other highlights in the February 4 issue of JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    TAG: Other highlights the August JNCI

    (Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
    (Date:5/14/2015)... NEW YORK , May 14, 2015 ... specializing in identity verification and online remote ... Instructure, a software-as-a-service (SaaS) company and creator ... Shared customers of the two companies will ... Proctortrack in Canvas. As a ...
    (Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
    Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
    (Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
    (Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
    (Date:5/20/2015)... , May 20, 2015 Veracyte, ... preliminary data demonstrating the ability of the company,s ... (IPF) from other interstitial lung diseases (ILDs) using ... classifier,s potential to help thousands of patients avoid ... in IPF diagnosis – a frequent challenge for ...
    (Date:5/20/2015)... Pa. , May 20, 2015  Select ... that the Federal Trade Commission granted early termination ... Antitrust Improvements Act of 1976, as amended, applicable ... MJ Acquisition Corporation, a joint venture that Select ... L.P. As previously announced, MJ Acquisition ...
    Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
    Cached News: